Placebo + Paclitaxel

DRUG2 trials

Sponsors

Vascular Biogenics Ltd. operating as VBL Therapeutics, Chengdu Kanghong Biotech Co., Ltd.

Conditions

Gastric CancerGastroesophageal CancerRecurrent Platinum Resistant Ovarian Cancer

Phase 2

Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy

Chengdu Kanghong Biotech Co., Ltd.Gastric Cancer, Gastroesophageal Cancer

Start: 2020-09-15End: 2022-01-15Target: 81Updated: 2020-09-18

Phase 3

A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)

CompletedNCT03398655

Vascular Biogenics Ltd. operating as VBL TherapeuticsRecurrent Platinum Resistant Ovarian Cancer

Start: 2017-12-19End: 2022-07-19Updated: 2023-01-10

Related Papers

Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)

Journal of Clinical Oncology2023-10-3119 citations

Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018).

Journal of Clinical Oncology2023-06-012 citations

Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).

Journal of Clinical Oncology2022-06-012 citations

Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).

Journal of Clinical Oncology2021-05-201 citations

Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.

2021-02-239 citations

Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).

Journal of Clinical Oncology2020-05-201 citations

Clinical trial in progress: A study of VB-111 combined with paclitaxel vs. paclitaxel for treatment of recurrent platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).

Journal of Clinical Oncology2018-05-202 citations